A bold move by President Trump has sparked a debate on the cost of weight loss medications. The potential impact on patients' wallets is a hot topic, and we're diving into the details.
Trump recently made headlines by striking deals with pharmaceutical giants Eli Lilly and Novo Nordisk to reduce the prices of their popular weight loss drugs. Under these agreements, patients could expect to pay anywhere from $50 to $350 per month for these medications, a significant drop from the current list prices exceeding $1,000.
But here's where it gets controversial: these deals are part of Trump's "most favored nation" policy, aiming to expand access to these drugs. Let's explore how these agreements could affect different groups of patients.
Medicare and the Obesity Drug Revolution
Medicare, the federal health insurance program, has traditionally covered GLP-1 drugs for diabetes and certain other conditions. However, under the new deals, Medicare will now cover these drugs for obesity treatment, starting mid-2026. This is a game-changer, as it could make these medications accessible to more seniors and potentially influence private insurers to follow suit.
Certain Medicare patients will pay a copay of $50 per month for all approved uses of GLP-1 drugs, including diabetes and obesity treatment. But the Trump administration has set specific criteria for eligibility, ensuring the drugs are targeted towards those who need them most.
Patients must fall into one of three cohorts to qualify for GLP-1s for obesity and cardiovascular and metabolic benefits: being overweight (BMI > 27) or having prediabetes or cardiovascular disease; having obesity (BMI > 30) with uncontrolled hypertension, kidney disease, or heart failure; or having severe obesity (BMI > 35).
Direct-to-Consumer Access and Pricing
The agreements also open up direct-to-consumer platforms for patients to access GLP-1s at discounted rates. On TrumpRx, the government's upcoming direct-to-consumer platform, the monthly cost for injectable GLP-1s like Wegovy and Zepbound will start at $350 and drop to $250 within two years. Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk will be $145 per month on TrumpRx, Medicare, and Medicaid.
Eli Lilly has announced it will lower prices by $50 on its direct-to-consumer platform, LillyDirect, offering Zepbound and other drugs at a discount to cash-paying patients. The multidose pen of Zepbound will be available for $299 per month at the lowest dose, with additional doses priced up to $449 per month. Once approved, Eli Lilly's pill will start at $149 per month for the lowest dose.
Medicaid and State Coverage
State Medicaid coverage of GLP-1 drugs for obesity is currently inconsistent. However, Novo Nordisk and Eli Lilly have agreed to extend lower government pricing for their GLP-1 drugs ($245 per month for all non-starting doses) to all 50 Medicaid programs for all covered uses. States have the option to opt into these prices, so it's essential to check with your state government regarding coverage.
This is a significant development in the world of weight loss medications, and it's sure to spark discussions. What are your thoughts on these deals? Do you think they will make a meaningful difference in access to these drugs? We'd love to hear your opinions in the comments below!
